NEW YORK (GenomeWeb) – Dermatology diagnostics firm Mindera today announced the close of its $1 million seed financing round.
The firm said in a statement that Scientific Health Development was among the investors in the oversubscribed round. Proceeds will go towards further validating Mindera's proprietary micro-needle technology and preparing for the launch of its first research products.
The South San Francisco, California-based firm makes a device for a painless, minimally invasive alternative to skin biopsy. PCR or next-generation sequencing analysis of the biomarkers extracted from the device can indicate the molecular profile of the sample. Mindera is pursuing both research and clinical applications for the device.
CEO and Co-founder Philippe Nore said that the firm was "looking forward to generating and publishing compelling data in the near future."
Fundraising in the skin cancer diagnostics space has been up and down in the past year. In April, melanoma testing firm DermTech raised $2.4 million; however, in November 2014 the firm withdrew a planned $15 million initial public offering.